Severe cutaneous adverse reaction associated with vemurafenib: <scp>DRESS</scp>,<scp> AGEP</scp> or overlap reaction?A. Gey, Thomas Jouary, Alain Taı̈eb et al.|Journal of the European Academy of Dermatology and Venereology|2014Cited by 30
Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!Camille Luherne, B. Milpied, A.‐S. Darrigade et al.|JAAD Case Reports|2019Cited by 4
List of critical drugs in dermatology: results of a Delphi consensus in FranceG. Chaby, M. Schöllhammer, S. Barbarot et al.|British Journal of Dermatology|2024Cited by 1